Movement Alert｜Praxis Precision Medicines, Inc. Rises 5.03% in Regular Trading, Recent Pipeline and Corporate Updates Support Shares

Market Focus10-28 23:49

On October 28, Praxis Precision Medicines, Inc. rose 5.03% in Regular Trading, trading at $280.54, with turnover of $30.7583 million.

The move coincided with continued market attention on the company’s recently disclosed business update and quarterly financial results, alongside multiple pipeline and partnership developments reported earlier in the year.

Previously, the company released an operational update and second-quarter financial results on August 6. Earlier, on July 7, Praxis Precision Medicines, Inc. announced a strategic collaboration with Remagine Labs to develop a transdermal formulation of ulixacaltamide for essential tremor. On June 30, the FDA extended by three months the review period for relutrigine in SCN2A- and SCN8A-related developmental epileptic encephalopathy. On June 2, vormatrigine showed favorable tolerability and stronger seizure reduction in the 30 mg cohort, although the Power1 study in refractory focal epilepsy did not meet its primary endpoint.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment